{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:26:42Z","timestamp":1761766002382},"reference-count":35,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T00:00:00Z","timestamp":1452816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T00:00:00Z","timestamp":1452816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Sanofi-Aventis Deutschland GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Prostate"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1002\/pros.23152","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T03:33:54Z","timestamp":1452915234000},"page":"613-619","source":"Crossref","is-referenced-by-count":12,"title":["Influence of abiraterone acetate on circulating neuromediators in chemotherapy-na\u00efve castration-resistant prostate cancer"],"prefix":"10.1002","volume":"76","author":[{"given":"Jost","family":"von Hardenberg","sequence":"first","affiliation":[{"name":"Department of Urology; Mannheim Medical Center; University of Heidelberg; Mannheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Urology; Mannheim Medical Center; University of Heidelberg; Mannheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Werner","sequence":"additional","affiliation":[{"name":"Outpatient Urology Practice; Herzberg am Harz Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Fuxius","sequence":"additional","affiliation":[{"name":"Outpatient Oncology Practice Heidelberg; Heidelberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Urology; Hospital Ludwigshafen; Ludwigshafen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[{"name":"Department of Urology; Mannheim Medical Center; University of Heidelberg; Mannheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"Wei\u00df","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics; Medical Faculty Mannheim; University of Heidelberg; Mannheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmar","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Department of Urology; University Hospital Goettingen; Goettingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,15]]},"reference":[{"key":"10.1002\/pros.23152-BIB0001|pros23152-cit-0001","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1002\/pros.23152-BIB0002|pros23152-cit-0002","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1002\/pros.23152-BIB0003|pros23152-cit-0003","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"49","key":"10.1002\/pros.23152-BIB0004|pros23152-cit-0004","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1002\/pros.23152-BIB0005|pros23152-cit-0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/pros.21042","article-title":"From pathogenesis to prevention of castration resistant prostate cancer","volume":"70","author":"Bonkhoff","year":"2010","journal-title":"Prostate"},{"issue":"5","key":"10.1002\/pros.23152-BIB0006|pros23152-cit-0006","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.humpath.2005.02.019","article-title":"Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma","volume":"36","author":"Grobholz","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1002\/pros.23152-BIB0007|pros23152-cit-0007","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fonc.2015.00037","article-title":"Prostate cancer and neuroendocrine differentiation: More neuronal, less endocrine","volume":"5","author":"Grigore","year":"2015","journal-title":"Front Oncol"},{"issue":"6","key":"10.1002\/pros.23152-BIB0008|pros23152-cit-0008","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1464-410X.2011.10523.x","article-title":"Survival of patients with small cell carcinoma of the prostate during 1973-2003: A population-based study","volume":"109","author":"Deorah","year":"2012","journal-title":"BJU Int"},{"key":"10.1002\/pros.23152-BIB0009|pros23152-cit-0009","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.5085","article-title":"Neuroendocrine differentiation patterns in metastases from advanced prostate cancer","volume":"32","author":"Jimenez","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1002\/pros.23152-BIB0010|pros23152-cit-0010","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.molonc.2015.02.010","article-title":"Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells \u2192 androgen receptor (AR) \u2192 miRNA32 signals","volume":"9","author":"Dang","year":"2015","journal-title":"Mol Oncol"},{"issue":"30","key":"10.1002\/pros.23152-BIB0011|pros23152-cit-0011","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2014.57.5100","article-title":"Neuroendocrine prostate cancer after hormonal therapy: Knowing is half the battle","volume":"32","author":"Tagawa","year":"2014","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1002\/pros.23152-BIB0012|pros23152-cit-0012","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1200\/JCO.2011.41.5166","article-title":"Challenges in recognizing treatment-related neuroendocrine prostate cancer","volume":"30","author":"Beltran","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1002\/pros.23152-BIB0013|pros23152-cit-0013","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.5003","article-title":"Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C\/PCF\/AACR West Coast Prostate Cancer","author":"Small","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1002\/pros.23152-BIB0014|pros23152-cit-0014","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1002\/pros.23152-BIB0015|pros23152-cit-0015","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.e16096","article-title":"Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC)","author":"Chaumard-Billotey","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1002\/pros.23152-BIB0016|pros23152-cit-0016","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1002\/pros.23152-BIB0017|pros23152-cit-0017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.eururo.2013.06.042","article-title":"Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone","volume":"65","author":"Schrader","year":"2014","journal-title":"Eur Urol"},{"issue":"3","key":"10.1002\/pros.23152-BIB0018|pros23152-cit-0018","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.clgc.2011.12.004","article-title":"Neuroendocrine differentiation in castration-resistant prostate cancer: A systematic diagnostic attempt","volume":"10","author":"Matei","year":"2012","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1002\/pros.23152-BIB0019|pros23152-cit-0019","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1530\/ERC-14-0071","article-title":"Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone","volume":"21","author":"Burgio","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1002\/pros.23152-BIB0020|pros23152-cit-0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/pros.10066","article-title":"Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate","volume":"51","author":"Ismail","year":"2002","journal-title":"Prostate"},{"issue":"6","key":"10.1002\/pros.23152-BIB0021|pros23152-cit-0021","first-page":"1221","article-title":"Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence","volume":"8","author":"Ito","year":"2001","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1002\/pros.23152-BIB0022|pros23152-cit-0022","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eururo.2005.03.017","article-title":"Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients","volume":"48","author":"Sasaki","year":"2005","journal-title":"Eur Urol"},{"issue":"2","key":"10.1002\/pros.23152-BIB0023|pros23152-cit-0023","first-page":"148","article-title":"Neuroendocrine differentiation in prostate cancer","volume":"1","author":"Sun","year":"2009","journal-title":"Am J Transl Res"},{"issue":"5","key":"10.1002\/pros.23152-BIB0024|pros23152-cit-0024","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ejca.2011.08.012","article-title":"Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments","volume":"48","author":"Korse","year":"2012","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.1002\/pros.23152-BIB0025|pros23152-cit-0025","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJM198605013141803","article-title":"Secretion of chromogranin A by peptide-producing endocrine neoplasms","volume":"314","author":"O'Connor","year":"1986","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/pros.23152-BIB0026|pros23152-cit-0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1677\/joe.0.1440049","article-title":"Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours","volume":"144","author":"Stridsberg","year":"1995","journal-title":"J Endocrinol"},{"issue":"4","key":"10.1002\/pros.23152-BIB0027|pros23152-cit-0027","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MPA.0b013e318243a0b6","article-title":"A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans","volume":"41","author":"Raines","year":"2012","journal-title":"Pancreas"},{"issue":"8","key":"10.1002\/pros.23152-BIB0028|pros23152-cit-0028","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/bjc.1998.635","article-title":"Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours","volume":"78","author":"Baudin","year":"1998","journal-title":"Br J Cancer"},{"issue":"7-8","key":"10.1002\/pros.23152-BIB0029|pros23152-cit-0029","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.prp.2004.06.002","article-title":"Augmented expression of chromogranin A and serotonin in peri-malignant benign prostate epithelium as compared to adenocarcinoma","volume":"200","author":"Sion-Vardy","year":"2004","journal-title":"Pathol Res Pract"},{"issue":"Suppl 2","key":"10.1002\/pros.23152-BIB0030|pros23152-cit-0030","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bju.12594","article-title":"Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues","volume":"113","author":"Ischia","year":"2014","journal-title":"Br J Urol Int"},{"issue":"20","key":"10.1002\/pros.23152-BIB0031|pros23152-cit-0031","doi-asserted-by":"crossref","first-page":"9835","DOI":"10.1158\/0008-5472.CAN-07-1886","article-title":"Transcriptional regulation of human protease-activated receptor 1: A role for the early growth response-1 protein in prostate cancer","volume":"67","author":"Salah","year":"2007","journal-title":"Cancer Res"},{"issue":"17","key":"10.1002\/pros.23152-BIB0032|pros23152-cit-0032","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1016\/j.ejca.2005.08.022","article-title":"Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling","volume":"41","author":"Stangelberger","year":"2005","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1002\/pros.23152-BIB0033|pros23152-cit-0033","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2967\/jnumed.113.121533","article-title":"A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer","volume":"54","author":"Liu","year":"2013","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1002\/pros.23152-BIB0034|pros23152-cit-0034","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/pros.10063","article-title":"Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients","volume":"51","author":"Yashi","year":"2002","journal-title":"Prostate"},{"issue":"3","key":"10.1002\/pros.23152-BIB0035|pros23152-cit-0035","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.juro.2007.05.018","article-title":"Chromogranin A expression in patients with hormone na\u00efve prostate cancer predicts the development of hormone refractory disease","volume":"178","author":"Berruti","year":"2007","journal-title":"J Urol"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23152","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23152","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pros.23152\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T09:59:17Z","timestamp":1596880757000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/pros.23152"}},"subtitle":["Abiraterone Acetate and Neuromediators"],"short-title":[],"issued":{"date-parts":[[2016,1,15]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,5]]}},"URL":"https:\/\/doi.org\/10.1002\/pros.23152","archive":["Portico"],"relation":{},"ISSN":["0270-4137"],"issn-type":[{"value":"0270-4137","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1,15]]}}}